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Cooperation of Human Tumor-Reactive CD4 and CD8
T Cells after Redirection of Their Specificity
by a High-Affinity p53A2.1-Specific TCR
a variety of different types of neoplastic cells provide
universal tumor- and leukemia-associated antigens
(TAA) presented as peptides via MHC class I molecules
for recognition by CD8 CTL (Melief et al., 2000). One
barrier to the development of TAA-based immunothera-
Ju¨rgen Kuball,1 FrankW. Schmitz,1,6 Ralf-Holger Voss,1
Edite Antunes Ferreira,1 Renate Engel,1
Philippe Guillaume,2 Susanne Strand,3
Pedro Romero,4 Christoph Huber,1 Linda A. Sherman,5
and Matthias Theobald1,*
peutics has been the observation that presentation of1Department of Hematology and Oncology
such antigens at low copy numbers by normal cells andJohannes Gutenberg University
tissues, including cells in the thymus (Gotter et al., 2004),55101 Mainz
results in a peripheral T cell repertoire that is devoid ofGermany
efficient TAA-specific, tumor-reactive CTL, due to self-2Ludwig Institute for Cancer Research
tolerance (Kuball et al., 2002; Theobald et al., 1997; Vier-Lausanne Branch
boom et al., 1997). We have previously reported that1066 Epalinges
HLA-A2.1 transgenic (tg) mice can be used to bypassSwitzerland
self-tolerance to human tumor-associated peptide-A2.13Department of Gastroenterology
(pA2.1) complexes and to generate efficient Ag-reactiveJohannes Gutenberg University
CTL (Stanislawski et al., 2001). The transfer of tumor-55101 Mainz
specific, wild-type (wt), and partially humanized TCRGermany
genes derived from double tg mice that express both4Division of Clinical Onco-Immunology
human CD8 and A2.1/Kb (A2Kb) turned human T lympho-Ludwig Institute for Cancer Research
cytes into fully competent, tumor- and leukemia-reactiveLausanne Branch
CTL, recognizing a naturally processed A2.1 bound pep-Hoˆpital Orthope´dique
tide comprising residues 81–88 of the human homolog1005 Lausanne
of the murine double-minute 2 oncoprotein, MDM2(81–Switzerland
88)A2.1 (Stanislawski et al., 2001).5Department of Immunology
The human tumor suppressor protein p53 comple-The Scripps Research Institute
ments MDM2 in cell cycle control, induction of apopto-La Jolla, California 92037
sis, and malignant transformation (Freedman and Lev-
ine, 1999). Mutation of p53 occurs in the majority of
human cancers and is associated with both cellular ac-Summary
cumulation of the protein and abrogation of its normal
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gets for tumor-specific CD8 CTL (Kuckelkorn et al.,suppressor protein. Retroviral expression of this CD8-
2002; Theobald et al., 1995, 1998; Vierboom et al., 2000).independent, p53-specific TCR into human T cells im-
However, aswithMDM2-derived peptides, the inductionparted the CD8 T lymphocyteswith broad tumor-spe-
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based immunotherapy of cancer is its dependency onandCD8CTL by the same high-affinity, CD8-indepen-
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Although the majority of malignant targets lack class II
MHC, precluding direct attack by CD4 Th cells, it hasIntroduction
been demonstrated that antigen-specific Th cell activity
is of pivotal importance for efficient eradication of suchProteins involved in the process of malignant cellular
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Figure 1. Expression and Avidity of a CD8-Independent p53(264–272)A2.1-Specific TCR in Human T Lymphocytes
(A) p53 TCR-transduced human T cells (Mu TCR p53), the TCR-parental A2 tg mouse CTL clone (CTL A2 p53.264 cl46), and MDM2 TCR-
transduced human T cells (Mu TCR MDM2) were tested by flow cytometry for expression of human CD4, the V3 domain of the p53-specific
TCR, and binding to tetrameric p53(264–272)A2.1 complexes.
(B) Mean fluorescense intensity (MFI) of p53(264–272)- or MDM2(81–88)A2.1 tetramer-labeled p53 or MDM2 TCR-transduced human CD8
and CD4 T lymphocytes in the presence or absence of an inhibiting anti-human-CD8 mAb (B9.11).
(C) Avidity (KD) of tetramer binding to T cells determined by Scatchard analysis. p53 or MDM2 TCR-transduced human CD8 (CD8 Mu TCR
p53 and CD8 Mu TCR MDM2), p53 TCR-transduced human CD4 T lymphocytes (CD4 Mu TCR p53), and the p53 TCR-parental A2 tg
mouseCTL clone (CTLA2 p53.264 cl46) were tested for binding towild-type (wt) (closed circles, wtTet) andmutated tetrameric p53(264–272)A2.1
or MDM2(81–88)A2.1 complexes (open circles, mutTet) by flow cytometry. Mutant tetramers harbor mutations in the 3 domain of A2.1 (D227K/
T228A) that abrogate binding to the human CD8 coreceptor.
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Table 1. Functional Avidity and Tetramer Binding Avidity of TCR-Transduced Human T Lymphocytes and Transgenic Mouse-Derived TCR-
Parental CTL
Functional Avidity (EC50) Tetramer Binding Avidity (KD)
51Cr-Release Flow Cytometry
 Anti-Mu-  Anti-Hu- IFN- Release Tet Mut Tet
T Cells CD8 (nM) CD8 (nM) (nM) (nM) (nM)
CTL CD8  A2 p53.264 4.2 132 n.d. n.d. n.d.
CTL A2 p53.264 cl46 6.7 2.2 n.d. 6.3 10.1
CD8 Mu TCR p53 0.02 0.07 0.2 1.7 14.6
CD4 Mu TCR p53 n.a. n.a. 33 21.8 32.5
CTL CD8  A2Kb MDM2 cl3 0.8 5.6 n.d. n.d. n.d.
CD8 Mu TCR MDM2 0.2 1.7 n.d. 6.3 w.b.
CD4 Mu TCR MDM2 n.a. n.a. n.a. n.b. n.b.
Abbreviations are as follows: n.a., no activity; n.b., no binding; n.d., not determined; and w.b., weak binding.
cytokine release (Gill and Lafferty, 1989; Ho et al., 2002; CD8 T cells benefit from the enhanced contribution to
binding of the p53A2.1 tetramer by human CD8. BindingJanssen et al., 2003) and by interactionwith professional
APC (Bennett et al., 1998; Ridge et al., 1998; Schoen- of p53A2.1 tetramers by the T cells under these condi-
tions appears to be determined predominantly by TCRberger et al., 1998; Snijders et al., 1998).
T lymphocytes from A2 tg mice are CD8 independent affinity. We observed only a weak effect on the intensity
of p53A2.1 tetramer staining after exposing p53 TCR-in their recognition of pA2.1, presumably due to their
selection and stimulation without a substantial contribu- transduced human CD8 T cells to an anti-human-CD8
mAb (Figure 1B). In contrast, CD8 T lymphocytes trans-tion by murine CD8, which cannot efficiently interact
with the human 3 domain of A2.1 (Sherman et al., 1992). duced with a MDM2(81–88)A2.1-specific TCR derived
from human CD8  A2Kb double tg mouse CTL (Stanis-In this report, we tested whether an A2.1-restricted TCR
from an A2 tg mouse was of sufficient affinity to turn lawski et al., 2001) showed a profound impairment of
their MDM2A2.1 tetramer binding intensity upon treat-human CD4 T cells without CD8 coreceptor participa-
tion into pA2.1-specific Th effectors by TCR gene trans- ment with the anti-human-CD8 mAb (Figure 1B). CD4
T cells transduced with the MDM2-specific, as opposedfer and to increase the avidity of human CTL that already
expressCD8. Here, we report on the targeted redirection to the p53-specific, TCR were unable to bind the pep-
tide-A2.1 tetramer (Figure 1B), although the mouse V6of both human CD4 Th cells and CD8 CTL by the
delivery of genes encoding a single, CD8-independent, subfamily domain of the transduced MDM2-reactive
TCR was expressed on the surface of almost all CD4high-affinity p53(264–272)A2.1-specific TCR intention-
ally developed in an A2 tg mouse. T lymphocytes. These observations indicate that the
transfer of a CD8-independent p53A2.1 versus a CD8-
dependent MDM2A2.1-specific TCR into human CD4Results
T cells was associated with binding of tetrameric
pA2.1 complexes.Delivery of a CD8-Independent p53-Specific TCR
into Human CD8 and CD4 T Cells
We cloned the full-length - and  chain sequences High Avidity of p53 TCR-Transduced
Human CD8 T Cellsencoding the p53(264–272)A2.1-specific TCR from a
CTL clone generated from an A2 tg mouse immunized The difference in the intensity of tetramer binding be-
tween p53 TCR-transduced CD8 and TCR-parental A2with this same peptide (Theobald et al., 1995) and used
this to transduce human peripheral blood mononuclear mouse CTL (Figure 1A) suggested that the delivery of
this TCR into human CD8 T lymphocytes would resultcells (PBMC). Almost all human CD8 and CD4 T cells
stained positive for the V3 subfamily domain of the tg in enhanced avidity mediated by the human CD8 core-
ceptor. Mutant tetramers harbor mutations in the 3mouse-derived p53-specific TCR after retroviral TCR
gene transduction andsubsequent selection (Figure 1A). domain of A2.1 (D227K/T228A) that abrogate binding to
the human CD8 coreceptor (Pittet et al., 2003). Pre-The majority of TCR-transduced CD8 T lymphocytes
and at least a substantial proportion of the CD4 subset venting the interaction of human CD8 with such mutant
(D227K/T228A) p53(264-272)A2.1 tetramers on p53 TCR-bound tetrameric p53(264–272)A2.1 complexes (Figure
1A). In contrast to both, no binding was detectable with transduced CD8 T cells led to an 8.6-fold decrease of
their avidity (KD), which was equivalent to the aviditiescontrol MDM2(81–88)A2.1 complexes (data not shown),
nor did T cells transduced with a MDM2(81–88)A2.1- (KD) determined for the parental A2 mouse CTL clone
(Figure 1C and Table 1). The slightly lower avidity (KD)specific TCR (Stanislawski et al., 2001) exhibit binding
of the p53A2.1 tetramers (Figure 1A). As compared to of the parental A2 mouse CTL clone determined with
mutant as compared to wt tetramers suggests a residualtheCD8T cell population,mean tetramer binding inten-
sity of p53 TCR human CD4 T cells was lower but interaction of murine CD8 with the 3 domain of human
pA2.1 (Figure 1C and Table 1). In contrast, almost noequivalent to binding by the TCR-parental A2 tg mouse
CTL clone (Figure 1A). This is consistent with the fact binding to mutant tetrameric MDM2(81–88)A2.1 com-
plexes was observed for MDM2 TCR-transduced CD8that neither the human CD4 T cells nor A2 tg mouse
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Figure 2. High Functional Avidity of Human CD8 CTL Transduced with a CD8-Independent p53A2.1-Specific TCR
Cytolytic activity (percentage of specific lysis) of p53 TCR-transduced human CD8 T cells (CD8 Mu TCR p53), the p53 TCR-parental A2 tg
mouse CTL clone (CTL A2 p53.264 cl46), a CD8  A2 double tg mouse-derived p53-specific CTL line (CTL CD8  A2 p53.264), or the MDM2
TCR-parental CD8  A2Kb double tg mouse CTL clone (CTL CD8  A2Kb MDM2 cl3) and MDM2 TCR-transduced human CD8 T cells (CD8
Mu TCR MDM2) in response to the indicated peptide-pulsed T2 targets and inhibiting anti-human-CD8 (OKT8) (open circles) and anti-mouse-
CD8 (3.168) (closed circles) mAb at the indicated effector to target ratios (E:T). The functional avidity was calculated as half maximum lysis
(EC50) from each blot.
T cells (Figure 1C and Table 1). Importantly, the avidities 1 to 100 nM (EC50 132 nM and 5.6 nM) (Figure 2 and
Table 1). Compared to the TCR-parental CD8  A2Kb(KD) of p53 TCR human CD4 T lymphocytes assessed
by staining with both wt and mutant pA2.1 tetramers tg CTL clone (EC50 0.8 nM), human CTL transduced
with the MDM2-specific TCR showed only a modestwere equivalent and almost within the range of those
obtained for p53 TCR human CD8 T cells or parental enhancement of their functional avidity (EC50 0.2 nM)
(Stanislawski et al., 2001), which was inhibited by themouse CTL by usingmutant or wt andmutant tetrameric
complexes, respectively (Figure 1C and Table 1). anti-human-CD8mAb (EC50 1.7 nM) (Figure 2 and Table
1). The 1.5- to 2-fold increase in molecule numbers ofOn a functional basis, TCR-transduced and purified
human CD8 CTL efficiently recognized the p53(264– humanCD8 on the surface ofMDM2TCRgene-modified
CD8 versus CD8  A2Kb tg mouse T cells has likely272) peptide at 0.1 nM, demonstrating a 2-log increase
of their functional avidity (EC50 0.02 nM) compared to contributed to their slightly differential avidity. The quan-
titative range of V3 or V6 molecules expressed onthe TCR-parental mouse CTL clone (EC50 2.2 and 6.7
nM) (Figure 2 and Table 1). At 0.1 nM of antigen, this TCR-parental mouse and TCR-transduced human CTL
specific for p53 or MDM2 was comparable (20,000–higher avidity was partially inhibited by an anti-human-
CD8 mAb (EC50 0.07 nM) (Figure 2 and Table 1). The 22,000 molecules/cell). These results demonstrate that
the expression of an A2 tg mouse-derived, CD8-inde-weak functional inhibition of the parental A2 mouse CTL
clone by an anti-mouse-CD8 mAb (EC50 2.2 versus 6.7 pendent TCR in CD8 human T lymphocytes led to their
enhanced functional avidity.nM) indicated again a residual interaction of murine CD8
with the 3 domain of human pA2.1 (Figure 2 and Table
1). In contrast, lysis of pA2.1 T2 targets by p53(264– Selective Recognition of Malignant Cells by p53
TCR-Transduced Human CD8 CTL272)- and MDM2(81–88)A2.1-specific CTL generated
from human CD8 A2 and CD8 A2Kb double tg mice, The purified p53 TCRCD8humanCTL killed efficiently
a wide variety of malignant A2.1 targets with alteredrespectively, was clearly affected by anti-human-CD8
mAb treatment at antigen concentrations ranging from p53 expression, but not p53-deficient Saos-2, NK-sensi-
CD8-Independent p53HLA-A*0201-Specific TCR
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Figure 3. Selective Recognition of Malignant Cells and Cytokine Release by High-Avidity p53 TCR-Transduced Human CD8 T Cells
(A and B) p53(264–272)A2.1-specific, TCR-transduced human CD8 CTL were tested at the indicated CD8V3 to target ratios (CD8V3:T)
for cytolytic activity (percentage of specific lysis) in response to p53A2.1 (closed circles, Saos-2/143; closed squares, UoC-B11; and closed
triangles, p53[264–272] peptide-pulsed K562-A2), p53A2.1 (open circles, Saos-2), p53A2.1 (open squares, UoC-B1), and p53A2.1 (open
triangles, K562) human tumor targets, and p53A2.1 human tumor cells (open circles, BT549; closed circles, MCF7; open triangles, SW480;
closed triangles, MZ1851RC; open squares, BV173; closed squares, JY; and open diamonds, IM9).
(C) The cytolytic activity of p53(274–272)A2.1-specific, TCR-transduced human CD8 CTL (black bars) was compared to that of the p53 TCR-
parental A2 tg mouse CTL clone (white bars) in response to p53A2.1 human tumor (MCF7, SW480, BT549) and control targets (Saos-2,
K562) at the indicated E:T ratio.
(D) Antigen-specific IFN- and IL-2 production at the indicated E:T ratios by p53(264–272)A2.1-reactive, TCR-transduced human CD8 T cells
(CD8 Mu TCR p53) in response to T2 or K562-A2 targets pulsed with the indicated peptides or after treatment with concanavalin A (Con A).
The functional avidity of cytokine-secreting p53 TCR human CD8 T cells was calculated as half maximum IFN- production (EC50).
(E) IFN- secretion by p53 TCR- (CD8 Mu TCR p53) or mock-transduced human CD8 T cells (CD8 Mock) at the indicated E:T ratio in
response to p53A2.1 (Saos-2/143, MZ1851RC, MDA-MB-231, MCF7, BV173, Ramos A2.1, UoC-B11, IM9, and JY), p53A2.1 (Saos-2), and
p53A2.1 or p53A2.1 (Ramos, UoC-B1, K562) tumor targets, and normal A2.1 human hepatocytes, fibroblasts (MRC-5), PBMC, and
activated CD8 T cells.
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Figure 4. Reeducation of Human CD4 Th Cells by the Delivery of a CD8-Independent p53A2.1-specific TCR
(A) IFN- secretion by human CD4 Th cells transduced with the CD8-independent p53(264–272)A2.1-specific TCR (CD4 Mu TCR p53), the
CD8-dependent MDM2(81–88)A2.1-specific TCR (CD4 Mu TCR MDM2), and mock (CD4 Mock) was tested at the indicated E:T ratio in
response to K562-A2 pulsed with the indicated peptides. The functional avidity of cytokine-secreting p53 TCR human CD4 T cells was
calculated as half maximum IFN- production (EC50).
(B) Antigen-specific IL-2, TNF-, and FasL secretion at the indicated E:T ratios by p53(264–272)A2.1-reactive TCR-transduced human CD4
Th cells (CD4 Mu TCR p53) in response to K562-A2 targets pulsed with the indicated peptides.
CD8-Independent p53HLA-A*0201-Specific TCR
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Figure 5. p53 TCR-Transduced Human CD4
T Cells Are Noncytolytic via Granzyme B and
Perforin but Mediate FasL-Dependent Inhibi-
tion of Tumor Cell Growth and Survival
(A) Cytolytic activity (percentage of specific
lysis) of p53(264–272)A2.1-specific TCR-trans-
duced human CD4 Th cells (open circles)
and the TCR-parental A2 tgmouseCTL clone
(closed circles) in response to T2 cells pulsed
with the indicated peptides at an E:T ratio
of 10:1.
(B andC) Anti-human-CD3/-CD28-stimulated
human CD8high, CD4CD8high, and CD4high T lym-
phocytes were tested for perforin expression
by flow cytometry. We observed a similar re-
sult for granzyme B expression.
(D) FasL-dependent inhibition of tumor cell
growth and survival by p53A2.1-specific hu-
man CD4 Th cells. Surviving Saos-2/143
cells after exposure to the TCR parental A2
tg mouse CTL clone (CTL A2 p53.264 cl46),
FluM1-specific CTL (CTL CD8A2Kb FluM1),
alloreactive A2.1-specific mouse CTL (CTL
CD8 allo A2), mock- (CD4 Mock) and p53
TCR-transduced human CD4 Th cells (CD4
Mu TCR p53), or p53 TCR-transduced human
bulk T cells (CD4/CD8 Mu TCR p53) at the
indicated E:T ratios. FasL and LY498919, a
deceoy receptor 3 analog that binds to and
blocks FasL, were added as indicated.
tive K562, or A2.1 UoCB1 cells (Figures 3A and 3B). tolytic and cytokine-secreting effector cells by the deliv-
ery of a CD8-independent p53(264–272)A2.1-specificConsistent with their enhanced avidity (Figures 1C and
2 and Table 1), TCR-transduced human CD8, as com- TCR.
pared to TCR-parental mouse CTL, were more efficient
in p53-specific tumor cell lysis (Figure 3C). In response Redirecting Human CD4 Th Cells
by a CD8-Independent p53-Specific TCRto peptide-pulsed stimulator cells, they specifically pro-
duced IFN- (EC50 0.2 nM) and IL-2 at a p53(264–272) Our tetramer analyses and anti-human-CD8mAb-based
inhibition studies (Figures 1 and 2 and Table 1) sug-antigen concentration as low as 0.1 nM (IFN-) (Figure
3D and Table 1). More importantly, they did so upon gested that the transfer of the CD8-independent p53
TCR into human CD4 T cells would reprogram themp53A2.1-specific recognition of tumor and leukemia
cellswhile ignoringK562 and normal A2.1 humanhepa- into pA2.1-specific Th cells. We found that selected and
purified p53 TCR-transduced CD4 Th cells were abletocytes, fibroblasts, PBMC, and activated CD8 T cells
(Figure 3E). We conclude that human CD8 T lympho- to specifically produce IFN- (EC50 33 nM), IL-2, and
TNF- upon p53(264–272)A2.1 recognition (Figures 4Acytes are turned into highly efficient, tumor-specific cy-
(C) Antigen-specific proliferation of CMFDA-stained p53 and MDM2 TCR-transduced CD4 T lymphocytes. In bold is the response of T cells
stimulated with the specific relative to the unrelated (nonbold) antigen loaded onto K562-A2.
(D) IFN- secretion by p53 TCR- or mock-transduced human CD4 Th cells at the indicated E:T ratio in response to human p53A2.1 (Saos-
2/143, MZ1851RC, MDA-MB-231, MCF7, IM9, JY, BV173), p53A2.1 (Saos-2, K562-A2), and p53A2.1 (K562) tumor targets.
(E) IFN- secretion by p53 TCR- or mock-transduced human CD4 (60%) and CD8 T cells (40%) at the indicated E:T ratio in response to
A2.1 human IFN-- and TNF--pretreated monocytes, immature (iDC) and mature DC (mDC), and PBMC, pulsed with either no or the
p53(264–272) peptide (P) at 106 M, and K562-A2 coated with either the p53(264–272) peptide (P) at 108 M or (X) each of a variety of known
A2.1 binding peptides, such as CD19(74–82), FluM1(58–66), gp100(280–288), HIV-RT(476–484), IE1(297–304), MDM2(81–88), p53(149–157),
p53(187–197), or tyrosinase(369–377) at 108 M. As this entire array of non-p53(264–272) peptides was not recognized at all by the p53 TCR-
transduced human T cells, a representative result is shown for K562-A2  X.
Immunity
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Figure 6. Interaction of p53A2.1-Specific TCR-
Transduced Human CD8 and CD4 T Cells
(A) Fold change in IFN- production in re-
sponse to peptide-pulsed T2 at the indicated
E:T ratio by combinations of human p53
(black and gray bars) or MDM2 (white bar)
TCR-transduced CD8 and CD4 T cells rela-
tive to either p53 TCR-transduced CD8
(black bar) or CD4 (gray bar) T cells, or
MDM2 TCR-transduced CD8 T cells (white
bar).
(B) Maturation of human iDC pulsed with the
indicated peptides is shown by flow cytome-
try and staining with anti-HLA-DR and -CD40
mAb after coincubation with p53 (Mu TCR
p53) (left) versus MDM2 TCR-transduced (Mu
TCR MDM2) (middle) human CD4 and a low
dose of CD8 T cells, or after addition of re-
combinant cytokines (right).
(C) Secretion of IL-12p70 by DC versus K562-
A2 after coincubation of peptide-pulsed iDC
or K562-A2 with p53 TCR- (Mu TCR p53) or
mock-transduced (Mock) human Tcells at the
indicated E:T ratios.
(D) Secretion of IL-12p70 by DC after coincu-
bation of iDC, pulsed with apoptotic or ne-
crotic Saos-2 or Saos-2/143 cells, with p53
TCR-transduced (Mu TCR p53) human CD4
(76%) and CD8 (24%) T cells at the indicated
E:T ratio.
and 4B and Table 1). In contrast, the transfer of MDM2 and mature (m) dendritic cells (DC), PBMC, and K562-A2
were not recognized by a combination of p53 TCR CD4TCR genes into CD4 T cells did not result in antigen-
specific cytokine release (Figure 4A). Consistent with and CD8 T cells unless they had been pulsed with the
p53(264–272) peptide (Figure 4E). Coating the same tar-this finding, we observed antigen-dependent prolifera-
tion of p53 TCR-transduced CD8 and CD4 as well as gets with a variety of known A2.1 binding peptides, such
as CD19(74–82), FluM1(58–66), gp100(280–288), HIV-RTMDM2 TCR-transduced CD8 T lymphocytes, but not
of MDM2 TCR-transduced CD4 T cells (Figure 4C and (476–484), IE1(297–304), MDM2(81–88), p53(149–157),
p53(187–197), and tyrosinase(369–377), did not result indata not shown). Although the p53 TCR CD4 Th cells
were of lower avidity as compared to the CD8 T cell IFN- release by p53 TCR-transduced CD4 and CD8
effector cells (Figure 4E). The p53 TCR CD4 Th weresubset (Figure 1C and Table 1), they were sufficiently effi-
cient to produce IFN- in specific response to naturally noncytolytic to peptide-pulsed T2 (Figure 5A) and K562-
A2 targets in a 4 hr 51Cr-release assay. Upon stimulationprocessed p53(264–272) presented by A2.1 on malignant
human cells, but not in response to p53-deficient A2.1 with anti-CD3 and anti-CD28, expression of granzyme B
andperforin was confined toCD8high and double-positiveSaos-2, K562, or K562-A2 stimulators (Figure 4D). Human
A2.1 IFN-- and TNF--treated monocytes, immature (i) CD4CD8high T cells but was absent from single-positive
CD8-Independent p53HLA-A*0201-Specific TCR
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CD4high Th cells (Figures 5B and 5C). However, after transduced CD4 and CD8 T cells had no substantial
effect on DC activation (Figure 6B), indicating that p53-a 48 hr coincubation, these p53 TCR CD4 Th cells
inhibited colony formation, growth, and survival of anti- specific DC maturation was exerted predominantly by
TCR-transduced CD4 T cells. Upon coculture with iDCFas (CD95 or APO-1)-sensitive, class II MHC-nega-
tive Saos-2/143 tumor targets (Figure 5D), presumably or K562-A2, these T cells also induced pA2.1-specific IL-
12p70 release by DC, but not by K562-A2 transfectantsthrough the production of Fas ligand (FasL or CD95L)
(Figure 4B). Consistent with this hypothesis, the addition (Figure 6C). Under these same conditions, IL-12p70 pro-
duction by DC as a result of their antigen-specific matu-of LY498919 (Wroblewski et al., 2003), a decoy receptor
3 analog that binds to and blocks the activities of FasL ration mediated by p53 TCR-transduced CD4 Th was
also induced in the presence of apoptotic or necroticand LIGHT (a TNF superfamily member, also known as
TNFSF-14, and ligand of stromal cell-expressed lympho- p53 Saos-2/143 tumor cells, but not in the presence
p53-deficient Saos-2 (Figure 6D). These results demon-toxin- receptor and T cell-expressed herpes viral entry
mediator), abrogated selectively the inhibiting effect on strate the synergistic cooperative properties, including
the potential of crosspresentation and crosspriming ofSaos-2/143 survival by both p53 TCR-transduced CD4
Th cells and the addition of FasL (Figure 5D). Further- DC and tumor-reactive CD4 and CD8 T cells engi-
neered to express the same, CD8-independent p53(264-more, incubation of p53 TCR-, but not mock-, trans-
duced CD4 Th cells with p53A2.1 MDA-MB-231 272)A2.1-specific TCR.
breast cancer cells resulted in an antigen-specific
upregulation of A2.1 and CD54 (ICAM-1) by 22% and Discussion
45%, respectively (data not shown). These studies set
the stage to investigatewhether direct and indirect cros- The development of a p53A2.1-specific TCR in A2 tg
stalk occurs between human CD4 Th cells and CD8 mouse to bypass tolerance to human p53 and to ensure
CTL redirected in their specificity by the same high- its CD8 coreceptor independence laid the basis for the
affinity p53(264–272)A2.1-specific tumor-reactive TCR. targeted redirection of both tumor-specific humanCD8
CTL and CD4 Th cells by retroviral TCR gene delivery.
These p53 TCR-transduced T lymphocyte subsets wereInteraction between p53 TCR-Transduced Human
CD4 Th Cells and CD8 CTL cooperative and interacted synergistically with DC and
tumor targets. Consistent with increased avidity regu-We found that the combination of p53 TCR-transduced
human CD8 and CD4 T cells produced 1.7- to 2.7- lated by the CD8 molecule (Holler and Kranz, 2003),
expression of the CD8-independent p53A2.1-specificfold more IFN- in response to p53(264–272)A2.1 than
did equal numbers (5 103) of either T cell subset alone TCR in CD8 human T lymphocytes led to a 2-log in-
crease of their avidity and functional efficiency as com-(Figure 6A). We observed a similar, up to 2.7-fold, in-
crease in IFN- release when the T cells were cocultured pared with the original murine CTL clone. Its partial inhi-
bition by a mutant pA2.1 tetramer and anti-human-CD8with malignant class II MHC-negative Saos-2/143 p53
transfectants and BV173 cells. In contrast, the coculture mAb at 0.1 nM of antigen suggests that the effect on
avidity regulation by membrane colocalization of CD8of CD8 and CD4 T cells engineered to express the
CD8-dependent MDM2-specific TCR had no advantage  homo- or  heterodimers and TCR depends on
TCR affinity and the copy number of pA2.1 presentedin MDM2(81–88)A2.1-specific cytokine secretion when
compared to MDM2 TCR CD8 effector cells (0.6-fold (Cawthon and Alexander-Miller, 2002; Holler and Kranz,
2003). Crystallographic resolution is required to evaluatedecrease) (Figure 6A).
After cognate class II pMHC recognition, CD4 Th whether the CD8 independence of the A2 tg mouse-
derived, p53-specific TCR is governed by an uniquecells deliver essential activation and maturation signals
to DC through CD40-CD40L interaction (Bennett et al., spatial orientation due to the placement of the TCR V
domain on the MHC (Buslepp et al., 2003).1998; Ridge et al., 1998; Schoenberger et al., 1998) and
IFN- release (Snijders et al., 1998). This results in upreg- The TCR expressed by the parental mouse CTL clone
was of sufficiently high avidity such that it could functionulation of antigen-presenting and costimulatory func-
tions by the DC, of which the latter are considered key without a requirement for an avidity boost by the CD8
coreceptor. In most cases, the overall avidity of a CD8for providing naive CTL with a license to kill (Bennett et
al., 1998; Ridge et al., 1998; Schoenberger et al., 1998; T cell represents contributions by both the TCR and the
CD8 coreceptor. One potential problem that could ariseSnijders et al., 1998). To determine whether the coincu-
bation of p53 TCR-transduced CD4 Th cells with in introducing high-affinity TCR into T cells that could
now increase their avidity by providing a functional core-p53(264–272)-pulsed iDC led to their maturation, cells
were cocultured. We observed DC maturation as indi- ceptor was that the T cell may no longer require the
presence of cognate peptide to trigger effector function.cated by an upregulation of HLA-DR (2.2-fold), CD40
(2.2-fold), CD80 (1.9-fold), CD83 (3.9-fold), and CD86 Indeed, this has been reported to occur when high-
affinity TCR were constructed by in vitro mutagenesis(1.4-fold) and a downregulation of CD1a (1.8-fold). Con-
sistent with synergistic IFN- production (Figure 6A), we (Holler et al., 2000). This was also observed previously
when we produced influenza matrix peptide-specific,found a further increase of HLA-DR and CD40 expres-
sion by DC in both, quantity (4.8- and 8.4-fold, respec- A2.1-restricted mouse CD8 CTL in A2 tg mice. Some
of these CD8 T cells were found to recognize A2Kb-tively) and intensity (1.8- and 3.1-fold, respectively) after
adding a low dose of p53 TCRCD8 T cells to the CD4 expressing targets in the absence of the matrix peptide.
For these clones, it appeared that the boost to avidityTh cell-DC coculture (Figure 6B). In contrast, labeling of
A2.1 iDC with MDM2(81–88) or the use of MDM2 TCR- that occurred due to the ability of mouse CD8 to interact
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with the 3 (H-2Kb) portion of the A2Kbmolecule resulted haploidentical hemopoetic stem cell transplants (Berger
in peptide-independent recognition of A2Kb (Sherman et al., 2001; Luznik et al., 2001; Ruggeri et al., 2002) may
et al., 1992). Fortunately, this was not observed to be a potentially ensure both the successful engraftment of
problem with the particular p53-reactive TCR used in such TCR-engineered autologous T cells and a milieu
the current studies, as the p53 TCR-transduced human of homeostasis that favors their expansion and survival
CD8 T cells did not lose the requirement for recognition in vivo (Dudley et al., 2002). Syngeneic mouse T cells
of the p53 peptide. transduced with a chimeric human pA2.1-specific TCR,
Direct and indirect interaction of tumor-reactive CD8 in which the human constant TCR  and  domains are
CTL with CD4 Th cells is essential for their sustained replaced by murine constant regions, will allow us to
activity, memory pool formation, and eradication of ma- study these options in adoptive transfer experiments
lignant cells (Ho et al., 2002; Janssen et al., 2003; Melief with A2.1 tgmice. As an alternative to tgmouse-derived,
et al., 2000; Pardoll and Topalian, 1998; Sun et al., 2004). high-affinity CD8-independent TCR molecules, TCR
Expression of the CD8-independent, p53-reactive TCR from allogeneic donors (Heemskerk et al., 2003, 2004;
in human CD4 T lymphocytes led to A2.1-restricted Th Stanislawski et al., 2001; Stauss, 1998) or ex vivo mu-
cells that were fully competent to interact with CD8 tated and selected TCR of high affinity (Holler et al.,
CTL, professional APC, and directly with class II MHC- 2000; Kessels et al., 2000) may, in theory, provide thera-
negative tumor cells. Interestingly, genetic changes, in- peutic instruments of human origin.
cluding p53 alterations, occur in the stromal tumor envi- In summary, our study on the intentional redirection
ronment as well (Kurose et al., 2002) and are thus likely of human CD4 Th cells and high-avidity CD8 CTL by
to be fair game for p53A2.1-specific recognition by TCR- the delivery of genes encoding a single, CD8-indepen-
redirected CD8 and CD4 effector cells. To study dent, and high-affinity p53A2.1-specific TCR lays the
whether the interaction of p53A2.1 TCR-transduced foundation for the exploitation of this approach for a
CD4 Th cells with DC and tumor cells could also license broad-spectrum immunotherapy of malignant disease.
CTL specific for other antigens whose crosspresenta-
tion coincides with p53 aberrations (Ossendorp et al., Experimental Procedures
1998), such as carcinoembryonic antigen (CEA) in colo-
rectal cancer and HER2/neu in breast cancer, requires Peptides, Antibodies, and Tetrameric pA2.1 Complexes
Peptides p53(149–157), (187–197), and (264–272); MDM2(81–88);careful evaluation in complex, genetically humanized
CD19(74–82); FluM1(58–66); gp100(280–288); HIV-RT(476–484);mouse models. Our observation that p53 TCR-repro-
IE1(297–304); and tyrosinase(369–377) (Stanislawski et al., 2001;grammed CD4 Th cells were able to induce antigen-
Theobald et al., 1995) were synthesized by Affina Immuntechnik
specific DC maturation in the presence of apoptotic or (Berlin, Germany). The mAb were anti-human-CD4-FITC, -PE, -CD8-
necrotic tumor cells certainly mimics more closely an PE, -PCY5, -HLA-DR-PE, -CD1a-PCY5, -CD80-FITC, -CD83-PCY5,
in vivo situation of crosspresentation, crosspriming, and -CD86-PE (Beckman Coulter, Krefeld, Germany), -CD40-FITC,
-CD54-PE, -perforin-PE, anti-mouse-V3-FITC, -V6-FITC (BD Bio-CD8 CTL licensing. An A2.1 tg human wt p53 knockin
science, Heidelberg, Germany), and anti-human-granzyme-B-FITCmousemodel additionally engineered to develop tumors
(Ho¨lzer Diagnostika, Ko¨ln, Germany). FluoroSpheres (Dako, Ham-that express human mutated p53 will allow us to study
burg, Germany) were used for quantifying TCR and CD8 expression.in vivo the single and combined effects of p53A2.1-
Blocking anti-human-CD8 (OKT8) and -mouse-CD8 (3.168) mAb
specific TCR-transduced syngeneic CD4 and CD8 were isolated from hybridomas and used in 51Cr-release assays
T cells on tumor eradication, potential autoimmunity, (Sherman et al., 1992). PE-labeled wt and mutated (D227K/T228A)
and memory pool formation. tetrameric pA2.1 complexes were synthesized as described (Ro-
mero et al., 1998; Pittet et al., 2003). Anti-human-CD8-PCY5 (B9.11)Self-tolerance appears to be less profound in the case
(Beckman Coulter) was used to inhibit wt tetramer staining.of p53-specific, class II MHC-restricted CD4 Th cell
responses (Zwaveling et al., 2002). In contrast to trans-
Cellsferring genes encoding a class II pMHC-reactive TCR
A2.1p53 cells were MZ1851RC (renal cancer); BT549, MCF7,into CD4 T cells (Chamoto et al., 2004), we took advan-
MDA-MB-231 (breast cancer); SW480 (colon cancer); UoC-B11,tage of a single CD8-independent class I pMHC-specific
BV173 (leukemia); IM9, JY (EBV-LCL); A2.1-transfected Ramos,TCR not only to simultaneously target both human CD4 Ramos-A2.1 (Burkitt’s lymphoma); and p53-deficient Saos-2 trans-
Th cells and CD8 CTL but also to equip the CD8 T cell fected with human mutant p53, Saos-2/143 (osteosarcoma) (Stanis-
subset with a high-affinity TCR specific for a self-tumor lawski et al., 2001; Theobald et al., 1995). A2.1p53 and p53 cells
antigen and to redirect CD4 T cells to class II MHC- were Ramos, UoC-B1 (leukemia), and NK-sensitive K562 (Stanislaw-
ski et al., 2001; Theobald et al., 1995). A2.1p53 cells were Saos-2,negative tumor targets.CD8-independent class I pMHC-
TAP-deficient T2, A2.1-transfected K562, K562-A2, MRC-5 (fibro-specific TCR expressed by CD4 or CD8 T cells are
blasts) (ATCC-LGC Promochem, Wesel, Germany, CCL-171), pri-normally a rare event (Roszkowski et al., 2003). There-
mary hepatocytes, PBMC, and activated CD8 T cells. Adherent
fore, the option of using high-affinity TCR derived from and nontransfected tumor targets were pretreated for 20 hr with
A2 tg mice to reeducate CD4 Th cells and intentionally recombinant human (rh)IFN- and rhTNF- (R&D, Wiesbaden, Ger-
break the affinity ceiling and CD8 dependence of tumor- many) at 20 and 3 ng/ml, respectively (Theobald et al., 1995). Human
reactive TCR is certainly an attractive option beyond A2.1monocyte-derived iDC and mDC were generated as reported
(Lotz et al., 2004; Stanislawski et al., 2001). To generate cytokine-p53 and an important new strategy for in vivo TCR-
treated human monocytes, PBMC were coated in a tissue culturebased cancer immunotherapy (Kessels et al., 2001). Al-
flask for 1 hr, and adherent cells were exposed to rhIFN- (20 ng/ml)though these TCR can be humanized for therapeutic
and rhTNF- (3 ng/ml) for 48 hr and harvested. Retroviral packaging
purposes (Stanislawski et al., 2001), they may still be lines were 293T (ATCC-LGC SD-3515) and Phoenix-Ampho (ATCC-
immunogenic in cancer patients (Berger et al., 2001, LGCSD-3443) (Stanislawski et al., 2001). Induction andmaintenance
2004). The strong immunosuppressive, (non)myeloabla- of p53(264–272)A2.1-, MDM2(81–88)A2.1-, and FluM1(58–66)A2.1-
specific CTL derived from CD8 A2 and CD8 A2Kb mice, respec-tive conditioning of patients who accept even HLA-
CD8-Independent p53HLA-A*0201-Specific TCR
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tively, and alloreactive A2.1-specific CTL has been reported (Kuball DC-derived IL-12p70, 5  104 peptide-pulsed iDC or 7  105 iDC
pulsed with 7  105 apoptotic (induced for 2 days by FasL at 500et al., 2002; Kuckelkorn et al., 2002; Theobald et al., 1997, 1998).
The p53(264–272)A2.1-specific CTL clone (CTL A2 p53.264 cl46) ng/ml once daily) or necrotic (induced by multiple freeze-thaw pro-
cedures) Saos-2 and Saos-2/143 cells, or K562-A2 were used.was generated from an A2 tg mouse-derived CTL line (Theobald et
al., 1995) by limiting dilution.
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